A top U.S. health official told a U.S. Senate committee that he expects Covid-19 vaccinations to take place over many months and that most Americans could be vaccinated by July 2021 at the latest.

In anticipation of data from a Phase III vaccine candidate study potentially becoming available in October, Germany’s BioNTech acquired a manufacturing facility from Novartis to boost production capabilities for the preventative treatment for the novel coronavirus.

Havas Health & You (HH&Y) announced the details of long-term global research project Behind the Mask, a longitudinal, multi-armed study which focuses on documenting the ongoing evolution of health and wellness.

In recognition of World Suicide Prevention Day, FCB Health New York announced the launch of “Disappearing Doctors,” a pro bono initiative advocating for and providing mental health support to physicians in need, in partnership with Sermo, Haymarket Media Group and the National Suicide Prevention Lifeline.

To quell concerns over the politicization of a potential vaccine for the novel coronavirus, nine pharmaceutical companies developing a preventative treatment signed a pledge promising to uphold the integrity of the scientific process ahead of any potential approval of a medication.

At least four of six different vaccine candidates financially backed by the U.S. government aimed at the novel coronavirus are predicted to fail in the clinic, according to a draft report from an analytics group cited by CNBC.

AstraZeneca Plc has begun enrolling adults for a U.S.-funded, 30,000-subject late-stage study of the company’s high-profile Covid-19 vaccine candidate.

The U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies. 

The United States is tying payments for Covid-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc. to meet ambitious targets.

(Reuters) – Any potential COVID-19 vaccine backed by the Trump administration’s “Operation Warp Speed” program is unlikely to receive a green light from regulators any earlier than November or December, given the time needed for a large-scale clinical trial, the National Institutes of Health director said on Thursday. In a call with reporters, Francis Collins […]